Miles Wang, an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the ChatGPT maker to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge of his plans. Several other OpenAI researchers are expected to join the new company. Wang is in talks to raise about $200 million at a $2 billion valuation, two of the people said. Lightspeed is in discussions to lead the funding round, according to sources. Talks are ongoing, the deal may not be final and details could change. Wang disputed the story’s funding figures and description of the company but did not specify the correct numbers or details. Wang’s new startup may be working on AI models that will help find new uses for existing drugs and possibly those that previously failed in trials, a couple of sources told TechCrunch. Wang joined OpenAI in 2024 after dropping out from Harvard, where he was working on a bachelor’s degree in computer science.